Prognostic impact of subepithelial Helicobacter pylori infection on clinical outcomes in patients with dyspepsia.

IF 2.2 4区 医学 Q4 IMMUNOLOGY
Apmis Pub Date : 2024-11-27 DOI:10.1111/apm.13503
Chalermpak Supakatitham, Kongsak Loharamtaweethong
{"title":"Prognostic impact of subepithelial Helicobacter pylori infection on clinical outcomes in patients with dyspepsia.","authors":"Chalermpak Supakatitham, Kongsak Loharamtaweethong","doi":"10.1111/apm.13503","DOIUrl":null,"url":null,"abstract":"<p><p>Several in vivo and in vitro studies have shown that Helicobacter pylori can invade epithelial cells and the lamina propria, potentially leading to underdiagnosis due to its subepithelial location. This retrospective study investigated H. pylori infection patterns and their impact on clinical improvement. Gastric tissue biopsies from 346 patients (August to December 2021) were studied using four commercially available immunohistochemical antibodies (TMDU, BioGenex, Cell Marque, and DAKO). The bacteria were graded based on their surface epithelial and subepithelial locations and then combined to establish an overall pattern. BioGenex, the antibody with the highest diagnostic performance due to its superior detection of surface and subepithelial cases, was selected as the gold standard for determining study outcomes. The isolated subepithelial H. pylori pattern was found to be an independent unfavorable prognostic feature. Patients with this pattern had the worst clinical outcomes compared to groups with isolated surface epithelial or other mixed patterns, which did not significantly differ. Subepithelial H. pylori should be included in pathological reports alongside the updated Sydney System. Further research should explore whether its eradication could improve treatment outcomes.</p>","PeriodicalId":8167,"journal":{"name":"Apmis","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Apmis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/apm.13503","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Several in vivo and in vitro studies have shown that Helicobacter pylori can invade epithelial cells and the lamina propria, potentially leading to underdiagnosis due to its subepithelial location. This retrospective study investigated H. pylori infection patterns and their impact on clinical improvement. Gastric tissue biopsies from 346 patients (August to December 2021) were studied using four commercially available immunohistochemical antibodies (TMDU, BioGenex, Cell Marque, and DAKO). The bacteria were graded based on their surface epithelial and subepithelial locations and then combined to establish an overall pattern. BioGenex, the antibody with the highest diagnostic performance due to its superior detection of surface and subepithelial cases, was selected as the gold standard for determining study outcomes. The isolated subepithelial H. pylori pattern was found to be an independent unfavorable prognostic feature. Patients with this pattern had the worst clinical outcomes compared to groups with isolated surface epithelial or other mixed patterns, which did not significantly differ. Subepithelial H. pylori should be included in pathological reports alongside the updated Sydney System. Further research should explore whether its eradication could improve treatment outcomes.

上皮下幽门螺杆菌感染对消化不良患者临床预后的影响。
多项体内和体外研究表明,幽门螺杆菌可侵入上皮细胞和固有层,可能因其位于上皮下而导致诊断不足。这项回顾性研究调查了幽门螺杆菌的感染模式及其对临床改善的影响。研究使用四种市售免疫组化抗体(TMDU、BioGenex、Cell Marque 和 DAKO)对 346 名患者(2021 年 8 月至 12 月)的胃组织活检进行了研究。根据细菌的表面上皮和上皮下位置对其进行分级,然后将其合并以确定整体模式。BioGenex 是诊断性能最高的抗体,对表面和上皮下病例的检测能力都很强,因此被选为确定研究结果的金标准。研究发现,孤立的上皮下幽门螺杆菌模式是一个独立的不利预后特征。与孤立的表面上皮或其他混合型幽门螺杆菌相比,具有这种模式的患者临床预后最差,两者没有显著差异。上皮下幽门螺杆菌应与更新的悉尼系统一起纳入病理报告。进一步的研究应探讨根除幽门螺杆菌是否能改善治疗效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Apmis
Apmis 医学-病理学
CiteScore
5.20
自引率
0.00%
发文量
91
审稿时长
2 months
期刊介绍: APMIS, formerly Acta Pathologica, Microbiologica et Immunologica Scandinavica, has been published since 1924 by the Scandinavian Societies for Medical Microbiology and Pathology as a non-profit-making scientific journal.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信